Search
News & Events
The science of immunisation: Questions and answersCommon myths about immunisation have been laid to rest in a new booklet written by top immunologists and published by the Australian Academy of Science.
Research
FluCAN - The Influenza Complications Alert NetworkThe main aim of the study is to provide timely surveillance data to public health authorities on severe influenza.
Research
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyDisease caused by Streptococcus pneumoniae is associated with considerable morbidity and mortality in children. Pneumococcal conjugate vaccines are well tolerated and effective at reducing pneumococcal disease caused by vaccine serotypes. VAXNEUVANCE (V114) is a 15-valent PCV containing 13 serotypes in Prevnar 13, plus serotypes 22F and 33F. This large phase 3 study evaluated safety and tolerability of V114 in infants.
Research
Excess respiratory mortality and hospitalizations associated with influenza in Australia, 2007-2015Influenza is the most common vaccine-preventable disease in Australia, causing significant morbidity and mortality. We assessed the burden of influenza across all ages in terms of influenza-associated mortality and hospitalizations using national mortality, hospital-discharge and influenza surveillance data.
Research
Efficacy and safety of influenza vaccination during pregnancy: realizing the potential of maternal influenza immunizationPregnant women are at higher risk of severe complications following influenza infection compared to the general population. Influenza vaccination during pregnancy can offer direct protection to pregnant women and passive immunity to infants up to 6 months of age via maternal antibodies. Pregnant women are a high priority group for influenza immunization.
Research
Tracking of activated cTfh cells following sequential influenza vaccinations reveals transcriptional profile of clonotypes driving a vaccine-induced immune responseA vaccine against influenza is available seasonally but is not 100% effective. A predictor of successful seroconversion in adults is an increase in activated circulating T follicular helper (cTfh) cells after vaccination. However, the impact of repeated annual vaccinations on long-term protection and seasonal vaccine efficacy remains unclear.
Research
S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccineBased on descriptive analyses of this small study, S. aureus 3-antigen vaccine vaccination did not impact S. aureus acquisition or carriage
Research
An economic case for a vaccine to prevent group A streptococcus skin infectionsA vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability
Research
Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical TrialThe monovalent acellular pertussis vaccine is immunogenic and safe in neonates
Research
Hesitant compliers': Qualitative analysis of concerned fully-vaccinating parentsParents interpreted pivotal vaccine-related events in the community as requiring them to take personal responsibility for vaccine decisions